在心房管理的进步:一般内科医生的指南
Hoang Nhat Pham1, Ramzi Ibrahim2, Hong Hieu Truong3
1Department of Medicine, University of Arizona, Tucson, AZ 85719, USA.
Journal of clinical medicine
|January 8, 2025
概括
新的心房指南强调早期检测和以患者为中心的护理. 一般内科医生可以通过采用这些更新的策略来管理这种常见的心律失常,从而改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
- 公共卫生 公共卫生
背景情况:
- 心房动 (AF) 是美国最常见的持续心律失常,影响数百万,预计到2030年将翻一番.
- AF显著增加中风和其他心血管事件的风险,导致显著的发病率和死亡率.
- 当前的管理模式正在不断发展,以应对AF日益增长的负担.
研究的目的:
- 审查2023年ACC/AHA/ACCP/HRS指南,用于心房的诊断和管理.
- 为一般内科医生提供有关更新的,以患者为中心的AF护理方法的见解.
- 要突出从基于持续时间的分类转向以风险因素为中心的综合战略的转变.
主要方法:
- 对2023年ACC/AHA/ACCP/HRS指南的分析.
- 检查了新的AF分类系统,强调早期检测和干预.
- 对多学科护理模式和初级保健提供者角色的建议的审查.
主要成果:
- 这些指南引入了转向以患者为中心的方法的范式转变,超越了基于持续时间的AF分类.
- 一个新的分类系统优先考虑早期检测,风险因素评估和量身定制的生活方式修改.
- 重点放在多学科护理模式上,赋予初级保健提供者主动AF管理的权力.
结论:
- 更新的指南提供了一个全面的框架,有效地管理心房动.
- 一般内科医生在实施风险因素管理和生活方式干预措施以预防和照顾AF方面是至关重要的.
- 采用这些指导方针可以提高患者的治疗结果,并应对AF管理的不断变化的局面.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Disturbances in Heart Rhythm
895
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
895
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
770
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
770
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
900
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
900
Adrenergic Antagonists: ɑ and β-Receptor Blockers
405
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
405


